Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Drug Licenses: A New Model For Pharmaceutical Pricing
Health Affairs, 01/09/08
Goldman DP et al. - High drug prices are a major barrier to patients’ access to drugs and compliance with treatment. Yet low drug prices are often argued to provide inadequate incentives for innovation. We propose a drug-licensing model for health care, which has the promise of increasing drug use without altering patients’ out-of-pocket spending, health plans’ costs, or drug companies’ profits
Related Articles
Amgen Provides Update on Status of Prolia Biologics License Application Submitted to the U.S. Food and Drug Administration
Amgen, 10/20/09
Relevance Score: 68%
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Relevance Score: 67%
Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09
Relevance Score: 66%
Human genome sciences receives complete response letter from fda for raxibacumab biologics license application
Human Genome Sciences, 11/17/09
Relevance Score: 66%
Dendreon Completes Submission of Biologics License Application for PROVENGE
Dendreon Coproration, 11/03/09
Relevance Score: 66%
Today in Licensure/Accreditation...keeping you current
Receive free subspecialty "5-minute updates" via email
EDI Accrediting Firm Updates Criteria
HealthDataManagement, 12/09/09
Consumer Demand for H1N1 Information Highlights Importance of Accreditation for Health Call Centers
URAC News Releases, 12/07/09
The Joint Commission’s Hospital Accreditation Recognized by CMS
Joint Commission news, 12/03/09
Article Search
Sponsor


See Latest Articles


